Gastroparesis may be involved in the pathophysiology of prolonged nausea and vomiting after haemopoietic stemcell transplantation (HSCT), but this has not been prospectively investigated. Gastric emptying (GE) was investigated in 20 patients before and 2 months after autologous HSCT. Gastrointestinal symptoms were graded prospectively and oral energy intake was recorded in parallel. Before transplant, all patients were asymptomatic and GE was within the reference range. Post transplant GE was delayed in three patients and three patients reported nausea and/or vomiting. Neither gastrointestinal symptoms nor oral energy intake post transplant discriminated between patients with or without delayed GE. Oral energy intake before transplant was lower (P ¼ 0.05), and there was a greater need for total parenteral nutrition (TPN) among patients who developed gastroparesis post transplant (Po0.05). Delayed GE after HSCT was found to be less common than had been believed from retrospective studies. Gastroparesis may be involved in some cases of prolonged nausea and vomiting after autologous HSCT but alternative explanations should be considered. Symptoms consistent with gastroparesis did not correlate with GE. Patients at risk of developing gastroparesis may be found among those with nutritional difficulties before and during the transplant course.
inal toxicity; prospective trial Haemopoietic stem-cell transplantation (HSCT) has improved the prognosis for patients with haematological malignancies [1] [2] [3] and encouraging results have also been achieved with some solid tumours. 4, 5 However, just as leukaemia and cancer cells are destroyed by the conditioning therapy, normal tissues with a high cell turnover rate will likewise be affected. Thus, the gastrointestinal (GI) tract will be one of the organ systems that restrict dose escalation in the treatment of patients with haematological malignancies and cancers. The use of modern, antiemetic drugs has dramatically decreased nausea and vomiting in the acute phase (0-24 h) after the conditioning treatment preceding HSCT. Instead, acute toxicity is currently dominated by painful oral ulcers, abdominal pains and diarrhoea. [6] [7] [8] These symptoms, reflecting damage to the entire GI tract, peak together with a disruption of the intestinal barrier function approximately 2 weeks after the start of the conditioning therapy but in the majority of the patients resolve and disappear a week later. 9 However, some patients experience nausea and vomiting for up to 2 months after the transplantation (prolonged post chemotherapy nausea and vomiting, PPNV). From retrospective observations, it has been suggested that gastroparesis may contribute to these symptoms but this has not been prospectively evaluated. [10] [11] [12] The aim of the current trial was therefore to prospectively evaluate the incidence of delayed GE as well as the GI symptoms after autologous HSCT in patients with haematological malignancies.
Materials and methods

Patients
A total of 20 patients with haematological malignancies undergoing autologous HSCT at the Department of Haematology, Sahlgrenska University Hospital, Gothenburg, Sweden, were included between June 1998 and February 2002. Five patients who accepted inclusion performed the GE test only before transplantation and were therefore excluded from the analysis. The reasons for not performing the post transplant examination were unwillingness to complete the study without giving a specific reason (n ¼ 3), the patient died before follow up (n ¼ 1) or technical problems (n ¼ 1). Another 71 patients underwent autologous HSCT during the study period but were not enrolled in the study (declined enrolment, n ¼ 20; enrolment unintentionally missed for organizational reasons, n ¼ 49; language difficulties, n ¼ 2).
Apart from their haematological malignancies the patients were otherwise healthy. Two patients with hypertension were receiving a b-blocker but no patients were on medication with drugs known to have a prokinetic effect (such as tacrolimus, erythromycin or cisapride) before or during the study period. No patient had a history of ischaemic heart disease and all patients were shown to have a normal ultracardiogram (UCG) before transplant. No patient fulfilled the criteria for diabetes mellitus before inclusion.
Baseline patient characteristics and conditioning of included (n ¼ 20) and excluded (n ¼ 71) patients will be found in Table 1 .
The study protocol was approved by the Ethical Committee and the Isotope Committee of Sahlgrenska University Hospital and all patients gave informed, written consent before inclusion.
Methods
All patients received the same prophylactic antibiotics (orally administered ciprofloxacin 1000 mg/day from day À5 until engraftment, and aciclovir 1200 mg/day from day À7 toþ 100). Antifungal prophylaxis (fluconazole 100-200 mg/day) was restricted to patients colonized with fungi prior to transplantation. In total, 14 patients were already on medication with aciclovir at the time of inclusion.
Antiemetic therapy (ondansetron) was given during conditioning therapy. Total parenteral nutrition (TPN) was generally started when the daily, oral, caloric intake decreased below 50% of basic needs and was tapered off and stopped when the daily caloric intake exceeded 50% of basic needs.
GE test
GE was evaluated using radiopaque markers (ROMs) 1 week before and approximately 2 months after transplant. At 8.00 am, 20 cubic ROMs with density 1.13 g/cm 3 and 3 mm side were given, together with a standard meal, which consisted of porridge and a soft drink (150 ml). The total energy content was 360 kcal. Emptying of ROMs was followed by hourly fluoroscopy, starting 4 h after ingestion until all ROMs were emptied. Emptying was regarded as delayed if any ROMs or more than 30% of ingested ROMs were retained after 6 h in men and women, respectively. 13 
Colonic transit time
In a subgroup of patients, colonic transit time was evaluated, using ROMs 1 week before (n ¼ 12) and approximately 2 months after transplant (n ¼ 9). It was evaluated by a single, plain, abdominal X-ray 7 days after the start of daily ingestion of 10 ring-shaped ROMs for 6 days. The number of retained ring markers divided by 10 (the daily dose) is the transit time in days.
Clinical GI toxicity
Clinical GI symptoms (nausea, vomiting, early satiety, obstipation and diarrhoea) were recorded prospectively by the patients during a 3-day period before transplant and during another 3-day period in connection with the post transplant, GE evaluation. During the same periods, patients recorded all oral intake. On the basis of these data, the mean, daily, oral energy intake was calculated for each individual. GI toxicity according to the WHO criteria 14 was recorded prospectively by a nurse during the transplant course (from admission until discharge).
Intestinal permeability
GI permeability was assessed by a 51
Cr-EDTA-absorption test 15 before the start of the cytotoxic treatment and 4 days after the stem-cell infusion. The 24-h, urinary excretion of 51 Cr-EDTA was expressed as the percentage of the dose given orally.
Malabsorption test (d-xylose test)
In 14 patients, small intestinal absorption was evaluated before and approximately 3 weeks after the stem-cell infusion, using a d-xylose test. Patients ingested 165 mmol of d-xylose in 500 ml of water and the amount of d-xylose excreted in a 5-h urine collection was measured. 16 
Table 1
Baseline clinical characteristics for included and not included patients 
Results
GE
Before transplant GE was within the reference range in all patients (including patients who did not complete the study). Post transplant GE (69727 days after stem-cell infusion) was delayed in three patients (15%).
Colonic transit time
In the subgroup of patients in whom colonic transit time was measured, all results were within the normal range (o 2.3. and o 4.3 days for men and women, respectively) before (n ¼ 12) and after transplant (64.2729.3 days; n ¼ 9, data not shown). Three patients were not examined post transplant owing to unintentionally missed intake of ROMs (n ¼ 2) and unwillingness to complete the study (n ¼ 1).
Clinical toxicity
Gastrointestinal symptoms were recorded by all patients before and after transplant. No patients reported symptoms prior to transplant, but three patients (15%) reported either nausea (n ¼ 1) or nausea and vomiting (n ¼ 2) post transplant. No GI symptoms were reported by the five patients who did not perform the second GE evaluation. Oral intake was recorded by all patients included before and after transplant. There was a tendency to inferior, oral energy intake before transplant and a significantly greater need for total parenteral nutrition (TPN) during the transplant course among patients who developed gastroparesis after transplant, but clinical GI toxicity according to the WHO was not helpful in identifying patients who developed gastroparesis (Table 2) . Post transplant GI symptoms did not discriminate between patients with or without gastroparesis since two out of three patients with delayed GE reported no GI symptoms. No patients developed insulin-dependent hyperglycemia or fulfilled the criteria for diabetes mellitus during or after the study period.
Intestinal permeability
Baseline permeability data were obtained from all patients, and on day 4 after stem-cell infusion from 14 patients. There was a significant increase in intestinal permeability on day 4, compared with the baseline (5.072.2% and 1.670.8%, respectively, Po0.0001), but there were no differences between patients with or without delayed GE post transplant (Table 2) .
Malabsorption test (d-xylose test)
Baseline d-xylose tests were obtained from 14 patients, and post transplant (2277 days after the stem-cell infusion) from nine patients. Missed values were due to nausea (n ¼ 2) or technical problems (n ¼ 3).
There was a significant decrease in d-xylose excretion post transplant, compared with the baseline (32.3712.9 and 46.8711.7 mmol/5 h, respectively, P ¼ 0.01). Only one patient with gastroparesis performed the post transplant test and therefore no comparisons between groups were made.
Discussion
The main finding in this prospective trial in patients undergoing autologous HSCT was that gastroparesis was diagnosed in only 15% of the patients 2 months post transplant. Furthermore, there was no correlation between gastroparesis and symptoms consistent with the diagnosis. However, patients who developed gastroparesis had nutritional difficulties even before, and during the transplant course.
Three out of 20 patients (15%) reported nausea and/or vomiting approximately 2 months post transplant, which touch upon the results of previous retrospective trials in HSCT patients. In these studies, mainly in allogeneic patients, the proportions of patients with gastroparesis among symptomatic patients have been high but have also varied considerably (53% 10 , 100% 11 and 80% 12 ). One explanation may be that graft-versus-host disease (GVHD) in the upper GI tract may influence the symptoms reported and possibly contribute to gastroparesis. 12 In addition, the patients were selected for severity of symptoms, while in the present study the patients were prospectively included and showed mild GI symptoms not requiring therapy. In the light of the finding that two out of three patients with gastroparesis did not report typical symptoms, there is reason to believe that gastroparesis may be subclinical and that the correlation between delayed emptying and symptoms is very weak. This has also been shown to be the case in other subgroups of patients, for example, in those with diabetes. 17 One of the shortcomings in retrospective trials has been the lack of evaluation of GE and symptoms before transplant, making it difficult to draw any conclusions as to whether delayed GE is caused by the treatment or depends on other factors. The finding in the present trial, that objective GI toxicity during the acute phase of the transplant course failed to predict the development of gastroparesis, gives support to the assumption that some patients may be prone to delayed GE after chemotherapy. On the other hand, the majority of patients with PPNV after HSCT with a conditioning containing cisplatinum for breast cancer turned out to have gastroparesis, 11 making it likely that the cause of delayed GE is due to both treatment-related and individual risk factors.
Methodological considerations (patients)
Patients undergoing allogeneic HSCT were not included, since GVHD in the upper GI tract and the use of drugs with prokinetic effect may exert an influence on the interpretation of symptoms and GE. 12, 18 A large proportion of patients fulfilling the criteria for inclusion was not included in the study. The main reasons were organizational problems and the fact that the patients regarded the GE evaluation as complicated. This emphasises the need for less complicated methods of evaluating GE in this subset of patients. In this context, different breath tests 19 have been tried but their possible inaccuracy and the need for cumbersome calculations may cause problems and more reliable and simplified tests are under development. 20 It is unlikely that patient drop-out influenced the outcome significantly, since there were no differences in baseline clinical characteristics between those included or excluded. It is therefore, plausible that the results will apply to patients with haematological malignancies undergoing autologous HSCT.
Five of the patients included did not perform the GE evaluation post transplant but in no case was the reason nausea or vomiting, which otherwise might have led to underestimation of the frequency of post transplant gastroparesis.
Methodological considerations (methods)
Scintigraphy is probably regarded as the best method of measuring GE, but this method is expensive and of limited availability. However, measuring GE with ROMs has been shown to be well correlated with scintigraphy in both patients and healthy subjects. 13, 21, 22 Hence, it is unlikely that the use of scintigraphy would have enabled us to identify a greater proportion of patients with gastroparesis.
It should be stressed that both methods necessitate separate reference values for men and women. 13, 23 In conclusion, gastroparesis may be involved in some cases of severe, prolonged nausea and vomiting after autologous HSCT, but the incidence seems to be much lower than has been believed from previous retrospective studies. This prospective trial shows that delayed GE did not correlate with symptoms, and therefore alternative explanations of PPNV should be considered. Patients at risk of developing gastroparesis may be found among those with nutritional difficulties before and during the transplant course. The cause of gastroparesis after high-dose chemotherapy is still a puzzle, but it is most likely multifactorial, including both individual and treatmentrelated factors.
